143 related articles for article (PubMed ID: 35856565)
1. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF.
Wang H; Wu S; Wang Y; Tang B
Cancer Biol Med; 2022 Jul; 19(7):945-7. PubMed ID: 35856565
[No Abstract] [Full Text] [Related]
2. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
Zhou T; Liu J; Xie Y; Yuan S; Guo Y; Bai W; Zhao K; Jiang W; Wang H; Wang H; Zhao T; Huang C; Gao S; Wang X; Yang S; Hao J
Gut; 2022 Feb; 71(2):357-371. PubMed ID: 33674341
[TBL] [Abstract][Full Text] [Related]
3. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.
Albino D; Longoni N; Curti L; Mello-Grand M; Pinton S; Civenni G; Thalmann G; D'Ambrosio G; Sarti M; Sessa F; Chiorino G; Catapano CV; Carbone GM
Cancer Res; 2012 Jun; 72(11):2889-900. PubMed ID: 22505649
[TBL] [Abstract][Full Text] [Related]
4. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.
Albino D; Civenni G; Rossi S; Mitra A; Catapano CV; Carbone GM
Oncotarget; 2016 Nov; 7(47):76756-76768. PubMed ID: 27732936
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.
Albino D; Civenni G; Dallavalle C; Roos M; Jahns H; Curti L; Rossi S; Pinton S; D'Ambrosio G; Sessa F; Hall J; Catapano CV; Carbone GM
Cancer Res; 2016 Jun; 76(12):3629-43. PubMed ID: 27197175
[TBL] [Abstract][Full Text] [Related]
6. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
[TBL] [Abstract][Full Text] [Related]
7. ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.
Zhao T; Jiang W; Wang X; Wang H; Zheng C; Li Y; Sun Y; Huang C; Han ZB; Yang S; Jia Z; Xie K; Ren H; Hao J
Cancer Res; 2017 Feb; 77(4):874-885. PubMed ID: 27923832
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Jin F; Xiao D; Zhao T; Yu M
Oncol Lett; 2020 Jan; 19(1):858-868. PubMed ID: 31897200
[TBL] [Abstract][Full Text] [Related]
9. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis.
Zhao T; Xiao D; Jin F; Sun X; Yu J; Wang H; Liu J; Cai W; Huang C; Wang X; Gao S; Liu Z; Yang S; Gao C; Hao J
Br J Cancer; 2022 Nov; 127(8):1461-1472. PubMed ID: 35986089
[TBL] [Abstract][Full Text] [Related]
10. Abnormal Localization and Tumor Suppressor Function of Epithelial Tissue-Specific Transcription Factor ESE3 in Esophageal Squamous Cell Carcinoma.
Wang L; Xing J; Cheng R; Shao Y; Li P; Zhu S; Zhang S
PLoS One; 2015; 10(5):e0126319. PubMed ID: 25950810
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
Chen Y; Zhu H; Wang Y; Song Y; Zhang P; Wang Z; Gao J; Li Z; Du Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824314. PubMed ID: 30803373
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.
Longoni N; Kunderfranco P; Pellini S; Albino D; Mello-Grand M; Pinton S; D'Ambrosio G; Sarti M; Sessa F; Chiorino G; Catapano CV; Carbone GM
Oncogene; 2013 May; 32(18):2315-24, 2324.e1-4. PubMed ID: 22733135
[TBL] [Abstract][Full Text] [Related]
14. CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells.
Hartl L; Duitman J; Aberson HL; Chen K; Dijk F; Roelofs JJTH; Dings MPG; Hooijer GKJ; Hernanda PY; Pan Q; Busch OR; Besselink MGH; Boerman T; Peppelenbosch MP; Bijlsma MF; Spek CA
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32906832
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.
Lyu Z; Ma M; Xu Y; Wang X; Zhu Y; Ren W; Li T
Int J Clin Oncol; 2020 Jul; 25(7):1334-1345. PubMed ID: 32347431
[TBL] [Abstract][Full Text] [Related]
16. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.
Cao D; Zhang Q; Wu LS; Salaria SN; Winter JW; Hruban RH; Goggins MS; Abbruzzese JL; Maitra A; Ho L
Mod Pathol; 2007 May; 20(5):570-8. PubMed ID: 17396143
[TBL] [Abstract][Full Text] [Related]
18. CCR4
Sharma V; Sachdeva N; Gupta V; Nada R; Jacob J; Sahni D; Aggarwal A
Immunobiology; 2022 May; 227(3):152210. PubMed ID: 35358941
[TBL] [Abstract][Full Text] [Related]
19. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma.
Oshima Y; Sano M; Kajiwara I; Ichimaru Y; Itaya T; Kuramochi T; Hayashi E; Kim J; Kitajima O; Masugi Y; Masamune A; Ijichi H; Ishii Y; Suzuki T
Br J Anaesth; 2022 Apr; 128(4):679-690. PubMed ID: 35120712
[TBL] [Abstract][Full Text] [Related]
20. Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma.
Wang L; Wang M; Hu C; Li P; Qiao Y; Xia Y; Liu L; Jiang X
Oncotarget; 2017 Sep; 8(38):62953-62961. PubMed ID: 28968962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
